Gene therapy imaging in patients for oncological applications

被引:0
作者
Iván Peñuelas
Uwe Haberkorn
Shahriar Yaghoubi
Sanjiv S. Gambhir
机构
[1] University of Navarra,Department of Nuclear Medicine, University Hospital
[2] University of Heidelberg,Department of Nuclear Medicine
[3] Stanford University,Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio
[4] Stanford University,X Program
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2005年 / 32卷
关键词
Gene therapy; Molecular imaging; Radionuclide imaging; Monitoring; Transgene expression;
D O I
暂无
中图分类号
学科分类号
摘要
Thus far, traditional methods for evaluating gene transfer and expression have been shown to be of limited value in the clinical arena. Consequently there is a real need to develop new methods that could be repeatedly and safely performed in patients for such purposes. Molecular imaging techniques for gene expression monitoring have been developed and successfully used in animal models, but their sensitivity and reproducibility need to be tested and validated in human studies. In this review, we present the current status of gene therapy-based anticancer strategies and show how molecular imaging, and more specifically radionuclide-based approaches, can be used in gene therapy procedures for oncological applications in humans. The basis of gene expression imaging is described and specific uses of these non-invasive procedures for gene therapy monitoring illustrated. Molecular imaging of transgene expression in humans and evaluation of response to gene-based therapeutic procedures are considered. The advantages of molecular imaging for whole-body monitoring of transgene expression as a way to permit measurement of important parameters in both target and non-target organs are also analyzed. The relevance of this technology for evaluation of the necessary vector dose and how it can be used to improve vector design are also examined. Finally, the advantages of designing a gene therapy-based clinical trial with imaging fully integrated from the very beginning are discussed and future perspectives for the development of these applications outlined.
引用
收藏
页码:S384 / S403
相关论文
共 546 条
[81]  
Quiroga J(2000)Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction Nat Med 6 933-937
[82]  
Herrero I(2001)Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors Gene Ther 8 1572-1579
[83]  
Mazzolini G(2004)PET imaging of somatostatin receptors using Hum Gene Ther 15 681-690
[84]  
Alfaro C(2000)Ga-DOTA- Eur J Nucl Med 27 731-743
[85]  
Sangro B(1999)-Phe J Nucl Med 40 1132-1137
[86]  
Feijoo E(2005)-Tyr Eur Radiol 15 1658-1666
[87]  
Ruiz J(2004)-octreotide: first results in patients with meningiomas J Nucl Med 45 1829-1837
[88]  
Benito A(2004)The type 2 human somatostatin receptor as a platform for reporter gene imaging J Nucl Med 45 1796-1803
[89]  
Hanke P(2005)PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel Radiol Clin North Am 43 189-204
[90]  
Serwe M(2004)F-labelled, carbohydrated analogue of octreotide Ann Nucl Med 18 669-674